Dr. Jianjun Fan currently serves as the Director of the Institute of Biotechnological Drugs at Quzhou Fudan Research Institute and the head of research teams. He is also the leader of the Antibody Engineering Platform at the Shanghai Engineering Technology Research Center for Immunotherapy Drugs. His primary research focuses on antibody molecule optimization and the development of innovative antibody drugs. In recent years, he has led and participated in the research and development of seven antibody drug varieties, two of which have received IND approval.  In terms of academic research, he has published over 90 SCI papers, with a total citation count exceeding 3,700. He has led and participated in more than 10 national and provincial-level projects, established an intelligent metabolite target and antibody drug screening platform based on metabolomics, secured one corporate collaboration project, and was selected as a Shanghai Rising Star in Science and Technology. Additionally, he holds the positions of Deputy Director and Committee Member in several national and Shanghai-based professional societies, including the Interferon and Cytokine Committee of the Chinese Society of Microbiology and the Pharmaceutical Biotechnology Product Quality Control Committee of the Chinese Pharmaceutical Biotechnology Association.